M&A Deal Summary |
|
|---|---|
| Date | 2020-05-26 |
| Target | Themis Bioscience |
| Sector | Life Science |
| Buyer(s) | Merck |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1891 |
| Sector | Life Science |
| Employees | 70,000 |
| Revenue | 64.2B USD (2024) |
Merck is a global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments: Pharmaceutical, Animal Health, Consumer Care and Alliances. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck was established in 1891 and is based in Rahway, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 24 of 37 |
| Sector: Life Science M&A | 21 of 34 |
| Type: Add-on Acquisition M&A Deals | 23 of 35 |
| Country: Austria M&A | 1 of 1 |
| Year: 2020 M&A | 2 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-13 |
Virbac SA - SENTINEL U.S. Rights
New Jersey, United States Virbac SA - SENTINEL U.S. Rights comprises two canine products Sentinel Flavor Tabs and Sentinel Spectrum which provides protection against 5 different kinds of parasites. |
Buy | $400M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-05 |
VelosBio
San Diego, California, United States VelosBio, Inc. is a clinical-stage biopharmaceutical company committed to transforming the lives of patients with cancer by developing first-in-class therapies targeting ROR1. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic malignancies and solid tumors. The company is utilizing its ROR1-targeting antibody-based technology to develop a pipeline of ADCs and bispecific antibody product candidates for the treatment of hematologic malignancies and solid tumors. VelosBio was founded in 2017 and is based in San Diego, California. |
Buy | $2.8B |
